View a case study on The Mayo Clinic's innovative research by clicking image below.
GHR Foundation is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on a game-changing undertaking – the prevention of Alzheimer’s disease. One important study GHR is supporting is The Mayo Clinic Study of Aging, which is working to define the impact of Alzheimer's on the population and develop a screening approach to identify those at risk.
View a case study on The Mayo Clinic's innovative research by clicking image below.
GHR supports innovative new approaches to address the impact of Alzheimer’s disease. If you are interested in learning more about GHR’s Health Initiative, contact us.
GHR Foundation is joining forces with philanthropic and industry partners to fund groundbreaking Alzheimer’s prevention research. One such partnership is the APOE trial, a prevention study that will launch by early 2016 and last five years. GHR has partnered with the Alzheimer’s Association and Fidelity Biosciences Research Initiative to provide $10 million in new research funding to support the study.
The API APOE4 trial, conducted by the Banner Alzheimer’s Institute in Phoenix, Arizona, is focused on how two new therapies may prevent or delay the development of Alzheimer’s symptoms in a population known to be at high risk for the disease because of their age and genetic status. The trial will test two different potential approaches to see if one or both can prevent the development of memory and thinking symptoms of Alzheimer’s.
The new funding will support three aspects of the API APOE4 trial, including the expansion of the Alzheimer’s Prevention Registry, the evaluation of two remote genetic counseling approaches and new scans including Tau PET imaging, amyloid PET imaging and FDG-PET imaging. If successful, the trial will not only to evaluate investigational prevention therapies, but will help find faster ways to evaluate promising prevention therapies in the future.
To learn more about how the Foundation is targeting funding to improve some of the largest research efforts in the field, contact us.
The fight against Alzheimer’s disease is making headlines. Fueled by research advances and popular culture attention, GHR-funded projects targeting Alzheimer's prevention are building public awareness. Grants making headlines include:
Recent headlines document important milestones in the fight against Alzheimer's. GHR supports research that inspires hope among those impacted by the disease and advances opportunities for real results. For more information, contact us.
Recently more than 700 Alzheimer’s disease researchers attended the seventh annual Clinical Trials in Alzheimer’s Disease (CTAD) Conference in Philadelphia to discuss new developments in the field. In a press release describing the conference, CTAD described two highlights: new investigational compounds and collaborations for Alzheimer’s prevention.
The latter described the progress made by the Collaboration for Alzheimer’s Prevention (CAP), an umbrella group including two studies funded, in part, by GHR—the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).
At the conference, director of DIAN-TU Randall Bateman spoke on the progress of the CAP partnership. Despite differences in populations, the four studies have found common ground on a clear set of cognitive domains to test and compare results. All CAP trials now also plan to use tau imaging, thanks to a partnership between the NIH and 10 industry partners.
CAP’s updates, while notable, are only a portion of the rapidly changing landscape of Alzheimer’s research. Other notable progressions presented at CTAD, such as the new compounds being developed and the creation of the Alzheimer’s Prevention Registry to accelerate enrollment in trials, will intersect with GHR’s Health Initiative’s involvement as organizations and researchers work together to find effective treatment.
GHR Foundation’s Health Program funds research to support the prevention of Alzheimer’s disease. The FoundationFuondation has committed more than $10 million over the next 5 years to scale up important research already underway, including some of the largest research efforts in the field.
One such research program is the A4 Study. This study, led by Harvard researcher Dr. Reisa Sperling and coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego, is a clinical trial focused on determining the effectiveness of prevention therapy before Alzheimer's disease impacts the brain.
Enrollment for the study is underway and researchers are currently looking for volunteers aged 65+ with normal memory function to be screened for an Alzheimer’s amyloid plaques. Those found eligible for the study will receive prevention treatment at locations across North America and Australia.
While all research is uncertain, the potential to turn the tide and provide hope for all families that face Alzheimer’s has never been more promising. If you know someone who might be qualified and interested in participating in the study, have them examine the eligibility requirements and learn more here. To learn more about partnering with GHR Foundation to fund innovative Alzheimer’s research, contact us.
The journal Clinics in Geriatric Medicine recently published the results of GHR-funded physician outreach efforts by the Minnesota/North Dakota Chapter of the Alzheimer’s Association. Published as part of a larger article titled, “Developing Dementia-Capable Health Care Systems,” the piece highlights the importance of engaging community-based organizations like the Alzheimer’s Association in connecting patients with caregivers.
The research shows how community-based organizations reinforce services commonly provided by social workers. These services range from providing information for physicians regarding caregiver education to referring community services. The Minnesota/North Dakota Chapter of the Alzheimer’s Association was specifically highlighted, due to its newly-developed network of providers and clinics, which made an important step in establishing dementia-capable health care by increasing the occurrence of direct contact between patients and physicians.
GHR supports innovative new approaches to address the impact of Alzheimer’s disease. Learn more about our grant making today.
GHR Foundation attended the Alzheimer’s Association International Conference. As an important platform to present research and trend information, the forum saw global news coverage on potential new diagnostics, findings related to lifestyle and international rates of prevalence.
A Wall Street Journal piece covering the conference entitled “Alzheimer's Disease Fight Focuses on Preventive Treatment” reinforces GHR’s focus on funding effective prevention therapies. It notes that “greater ability to measure the progression of the disease in the brain through the use of biological markers, such as the imaging of disease-related proteins, has made it easier to detect the subtle and slow progression of the disease...”
To advance our Alzheimer’s strategy, GHR’s Alzheimer’s advisory council convened a strategic meeting at the conference to discuss the impact of research, potential collaboration and next steps. The Foundation is pleased to be partnering with so many public and private sectors leaders in the fight against Alzheimer’s disease.
With a focus on Alzheimer’s disease prevention research, GHR Foundation funded a groundbreaking Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study which may help identify people who are highest risk to develop the disease. This research will also identify treatments – and when to best administer them – to slow or prevent Alzheimer’s. Long-term, the Foundation hopes the A4 study and complementary research will result in FDA approval for Alzheimer’s prevention therapies.
The A4 study team is continuing to develop the clinical partnerships necessary to study 1,000 patients and has created tools to share background with potential participants. GHR Alzheimer’s advisory board member and lead A4 researcher Dr. Reisa Sperling explains the research and how people can get involved in the research in a recent YouTube video.
GHR looks forward to learning more about the impact of A4 on early detection and treatment of Alzheimer’s disease.